🚀 VC round data is live in beta, check it out!
Intercure Valuation Multiples
Discover revenue and EBITDA valuation multiples for Intercure and similar public comparables like SyntekaBio, Aligos Therapeutics, Dare Bioscience, J. Molner and more.
Intercure Overview
About Intercure
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
Founded
1994
HQ
Employees
390
Website
Financials (FY)
EV
$85M
Intercure Financials
Intercure reported last fiscal year revenue of $80M and negative EBITDA of ($17M).
In the same fiscal year, Intercure generated $10M in gross profit, ($17M) in EBITDA losses, and had net loss of ($23M).
Intercure P&L
In the most recent fiscal year, Intercure reported revenue of $80M and EBITDA of ($17M).
Intercure expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $80M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $10M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 13% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($17M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (21%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (19%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($23M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (28%) | XXX | XXX | XXX |
| Net Debt | — | — | $35M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Intercure Stock Performance
Intercure has current market cap of $42M, and enterprise value of $85M.
Market Cap Evolution
Intercure's stock price is $0.77.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $85M | $42M | 2.1% | XXX | XXX | XXX | $-0.41 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIntercure Valuation Multiples
Intercure trades at 1.1x EV/Revenue multiple, and (4.9x) EV/EBITDA.
Intercure Financial Valuation Multiples
As of April 18, 2026, Intercure has market cap of $42M and EV of $85M.
Equity research analysts estimate Intercure's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Intercure has a P/E ratio of (1.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $42M | XXX | $42M | XXX | XXX | XXX |
| EV (current) | $85M | XXX | $85M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (4.9x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (5.6x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 8.4x | XXX | XXX | XXX |
| P/E | — | XXX | (1.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Intercure Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Intercure Margins & Growth Rates
Intercure's revenue in the last fiscal year declined by (33%).
Intercure's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Intercure Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (33%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (21%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 115% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 26% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Intercure Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Intercure | XXX | XXX | XXX | XXX | XXX | XXX |
| SyntekaBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Aligos Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Dare Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| J. Molner | XXX | XXX | XXX | XXX | XXX | XXX |
| Neurizon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Intercure M&A Activity
Intercure acquired XXX companies to date.
Last acquisition by Intercure was on XXXXXXXX, XXXXX. Intercure acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Intercure
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIntercure Investment Activity
Intercure invested in XXX companies to date.
Intercure made its latest investment on XXXXXXXX, XXXXX. Intercure invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Intercure
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Intercure
| When was Intercure founded? | Intercure was founded in 1994. |
| Where is Intercure headquartered? | Intercure is headquartered in Israel. |
| How many employees does Intercure have? | As of today, Intercure has over 390 employees. |
| Who is the CEO of Intercure? | Intercure's CEO is Alexander Rabinovich. |
| Is Intercure publicly listed? | Yes, Intercure is a public company listed on Tel Aviv Stock Exchange. |
| What is the stock symbol of Intercure? | Intercure trades under INCR ticker. |
| When did Intercure go public? | Intercure went public in 2007. |
| Who are competitors of Intercure? | Intercure main competitors are SyntekaBio, Aligos Therapeutics, Dare Bioscience, J. Molner. |
| What is the current market cap of Intercure? | Intercure's current market cap is $42M. |
| What is the current revenue of Intercure? | Intercure's last fiscal year revenue is $80M. |
| What is the current EV/Revenue multiple of Intercure? | Current revenue multiple of Intercure is 1.1x. |
| Is Intercure profitable? | No, Intercure is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.